<DOC>
	<DOCNO>NCT01880840</DOCNO>
	<brief_summary>The purpose study compare safety 2 different dos investigational use allergy medication ( Astepro Nasal Spray ) treatment allergic rhinitis ( AR ) . This open-label study ; , parent child know group .</brief_summary>
	<brief_title>Safety Astepro 0.15 % Nasal Spray Astepro 0.1 % Nasal Spray Children Ages &gt; 6 Months &lt; 6 Years With AR</brief_title>
	<detailed_description>Approximately 200 subject , age ≥ 6 month &lt; 6 year age history AR participate study . The study conduct 20 research center United States . Each research center enroll approximately 2 10 subject . The study involve least 4 office visit least 4-week period . You need keep appointment schedule study personnel . Some medication therapy could interfere safety evaluation conduct study . If child currently take medication therapy , need discontinue order eligible study . Your study doctor discus along information could affect child 's health . If study doctor decide appropriate , specific time period need discontinue child proceed study evaluation . If child eligible study participation , he/she randomly assign ( chance , like flip coin ) one follow two study drug group : - Astepro ( azelastine hydrochloride ) 0.15 % Nasal Spray , 822 mcg ( total daily dose ) ; OR - Astepro ( azelastine hydrochloride ) 0.1 % Nasal Spray , 548 mcg ( total daily dose ) The follow performed purpose study consider standard care : - Your child place one two study drug group chance . - You complete questionnaire child 's allergy symptom . - You complete diary card morning record child 's allergy symptom previous 24 hour . - Your child his/her vital sign measure ( blood pressure , pulse , temperature breathe rate ) . - You child asked question regard child 's use medication supplement child felt since his/her last visit . - Blood urine sample collect assess safety take study drug .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female subject &gt; 6 month &lt; 6 year , inclusive screen visit A history AR The parent must provide write informed consent child must provide assent , possible Willing able comply study requirement May benefit treatment Astepro Nasal Spray , base Investigator 's assessment ( base medical history , physical examination , etc . ) subject 's clinical condition , Screening Randomization Visits General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer Subjects receive immunotherapy injection ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimen follow brief period miss injection preclude participation ) On nasal examination , subject superficial nasal mucosal erosion , moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation Other nasal disease ( ) likely affect deposition intranasal medication , acute sinusitis , rhinitis medicamentosa clinically significant polyposis nasal structural abnormality Nasal surgery sinus surgery within previous year Chronic sinusitis The use investigational drug within 30 day prior Visit 1 . No investigational product permit use conduct study Presence hypersensitivity drug similar azelastine either sorbitol sucralose ( Splenda® brand sweetener ) Respiratory tract infection within two week prior Visit 1 . Subjects significant pulmonary disease include asthma . Subjects intermittent asthma require shortacting inhaled bronchodilator eligible enrollment . Asthma ( exception intermittent asthma ) . Subjects intermittent asthma require shortacting inhaled bronchodilator ( often twice per week ) nocturnal awaken result asthma eligible enrollment Chronic obstructive sleep apnea syndrome ( clinical diagnosis ) Existence surgical medical condition , opinion investigator sponsor 's medical monitor , might significantly alter absorption , distribution , metabolism , excretion study drug might significantly affect subject 's ability complete trial Clinically relevant abnormal physical finding laboratory result , opinion investigator , would interfere objective Family member research center private practice personnel directly involve study exclude Members family enroll study time . Subjects use medication therapy could interfere safety evaluation ( see Section 4.0 ) Any behavioral condition could affect subject 's ability accurately report symptom caregiver developmental delay , attention deficit disorder , autism</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>